{"protocolSection":{"identificationModule":{"nctId":"NCT03564444","orgStudyIdInfo":{"id":"D2560C00015"},"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"D2560C00015 FluMist Annual Safety Study 2018","officialTitle":"A Phase 4, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety of 2 New of 6:2 Influenza Virus Reassortants in Adults"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-06-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-12-27","type":"ACTUAL"},"completionDateStruct":{"date":"2018-12-27","type":"ACTUAL"},"studyFirstSubmitDate":"2018-06-11","studyFirstSubmitQcDate":"2018-06-11","studyFirstPostDateStruct":{"date":"2018-06-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-12-10","resultsFirstSubmitQcDate":"2019-12-10","resultsFirstPostDateStruct":{"date":"2019-12-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-12-10","lastUpdatePostDateStruct":{"date":"2019-12-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.","detailedDescription":"This prospective. randomized, double-blind. placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age (not yet reached their 50th birthday). Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of bivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site. This study will be conducted at 2 sites in the United States of America. Each subject will receive 1 dose of investigational product on Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination."},"conditionsModule":{"conditions":["Influenza","Healthy"],"keywords":["Bivalent.","Influenza.","FluMist Quadrivalent.","Vaccine Prevention in Healthy Adults."]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":300,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bivalent influenza vaccine","type":"EXPERIMENTAL","description":"A single dose of bivalent vaccine (10\\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1","interventionNames":["Biological: Bivalent influenza vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Bivalent influenza vaccine","description":"A single dose of bivalent vaccine (10\\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.","armGroupLabels":["Bivalent influenza vaccine"]},{"type":"OTHER","name":"Placebo","description":"A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Reporting Fever (Oral Temperature >= 101 Degrees Fahrenheit) Through Day 8","description":"Percentage of participants with fever (oral temperature \\>= 101 degrees Fahrenheit) through Day 8 is reported.","timeFrame":"Day 1 through Day 8"}],"secondaryOutcomes":[{"measure":"Number of Participants With Solicited Symptoms Through Day 8","description":"For this study, solicited symptoms included oral fever (\\> 100 degrees Fahrenheit), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity (tiredness), and headache.","timeFrame":"Day 1 through Day 8"},{"measure":"Number of Participants With Solicited Symptoms Through Day 15","description":"For this study, solicited symptoms included oral fever (\\> 100 degrees Fahrenheit), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity (tiredness), and headache.","timeFrame":"Day 1 through Day 15"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Day 8 and Day 15","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","timeFrame":"Day 1 through Day 8; Day 1 through Day 15"},{"measure":"Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Through Day 29 and Day 181","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","timeFrame":"Day 1 through Day 29; Day 1 through Day 181"},{"measure":"Number of Participants With New Onset Chronic Diseases (NOCDs) Through Day 29 and Day 181","description":"An NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant.","timeFrame":"Day 1 through Day 29; Day 1 through Day 181"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 through 49 years\n* Written informed consent\n* Subject available by telephone\n* Ability to understand and comply with the requirements of the protocol, as judged by the Investigator\n\nExclusion Criteria:\n\n* Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)\n* History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations\n* Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example (eg\\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renaldysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year\n* Acute febrile (greater than \\[\\>\\]100.0 degrees Fahrenheit \\[F\\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days to randomization\n* Any known immunosuppressive condition or immune deficiency diseases, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy\n* History of Guillain-Barre syndrome.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Nathan Segall, MD","affiliation":"Clinical Research Atlanta","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Keith Klatt, MD","affiliation":"Columbia Research Group","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Protocol and Statistical Analysis Plan (SAP)","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D2560C00015&amp;attachmentIdentifier=8e50bdf3-f051-45ee-a9e9-e40b1d25de6c&amp;fileName=d2560c00015-csp-v1_Redacted.pdf&amp;versionIdentifier="}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The study was conducted between 06Jun2018 and 27Dec2018 in the USA.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"FG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"240"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"240"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) population included all randomized and treated participants, grouped according to actual treatment.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"BG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"240"},{"groupId":"BG002","value":"300"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.5","spread":"8.6"},{"groupId":"BG001","value":"30.5","spread":"8.9"},{"groupId":"BG002","value":"30.3","spread":"8.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"139"},{"groupId":"BG002","value":"173"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"127"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"16"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"284"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"64"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"214"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"11"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Reporting Fever (Oral Temperature >= 101 Degrees Fahrenheit) Through Day 8","description":"Percentage of participants with fever (oral temperature \\>= 101 degrees Fahrenheit) through Day 8 is reported.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 1 through Day 8","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.7","ciUpperLimit":"1.9"}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Symptoms Through Day 8","description":"For this study, solicited symptoms included oral fever (\\> 100 degrees Fahrenheit), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity (tiredness), and headache.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 8","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":">100 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":">102 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":">103 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Runny nose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"33"}]}]},{"title":"Sore throat","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"14"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Decreased activity (tiredness)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"27"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Symptoms Through Day 15","description":"For this study, solicited symptoms included oral fever (\\> 100 degrees Fahrenheit), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity (tiredness), and headache.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 15","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":">100 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":">=101 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":">102 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":">103 degrees Fahrenheit","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Runny nose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"37"}]}]},{"title":"Sore throat","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"17"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}]}]},{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"Decreased activity (tiredness)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"33"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Day 8 and Day 15","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 8; Day 1 through Day 15","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"TEAEs through Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"15"}]}]},{"title":"TEAEs through Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"19"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Through Day 29 and Day 181","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 29; Day 1 through Day 181","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"TESAEs through Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"TESAEs through Day 181","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New Onset Chronic Diseases (NOCDs) Through Day 29 and Day 181","description":"An NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant.","populationDescription":"The ITT population included all randomized and treated participants, grouped according to actual treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 29; Day 1 through Day 181","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray."},{"id":"OG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"NOCDs through Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"NOCDs through Day 181","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"For SAEs: Day 1 through Day 181 For non-serious AEs: Day 1 through Day 15","description":"An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience(immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received a single dose of placebo matched to bivalent vaccine by intranasal spray.","deathsNumAffected":0,"deathsNumAtRisk":60,"seriousNumAffected":0,"seriousNumAtRisk":60,"otherNumAffected":2,"otherNumAtRisk":60},{"id":"EG001","title":"Bivalent Vaccine","description":"Participants received a single dose of bivalent vaccine by intranasal spray.","deathsNumAffected":0,"deathsNumAtRisk":240,"seriousNumAffected":1,"seriousNumAtRisk":240,"otherNumAffected":19,"otherNumAtRisk":240}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]}],"otherEvents":[{"term":"Ear discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":240}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Stress fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":240}]},{"term":"Nasal pruritus","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":240}]},{"term":"Paranasal sinus discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":240}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":240}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."},"pointOfContact":{"title":"Raburn Mallory","organization":"MedImmune, LLC","email":"information.center@astrazeneca.com","phone":"+1-301-398-5799"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-03-27","uploadDate":"2019-11-21T05:05","filename":"Prot_SAP_000.pdf","size":16724643}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}